Summary
In previous investigations we found an increase of D2 dopamine receptors in the striatum of patients with nocturnal myoclonus syndrome (NMS) after treatment with dopamimetics. Under the hypothesis, that, according to animal experiments, the glutamatergic system could be involved in this atypical dopaminergic up-regulation in NMS. The glutamate release inhibitor lamotrigine was tested in up to now two NMS patients. The results and the success of this approach and its implications are discussed.
This is a preview of subscription content, log in via an institution to check access.
References
Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12(10): 366–375
Burns LH, Everitt BJ, Kelley AE, Robbins TW (1994) Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. Psychopharmacol 115: 516–528
DeLong MR (1990) Primate models of movement disorders of the basal ganglia origin. Trends Neurosci 13(7): 281–285
Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1): 1–24
Greenamyre JT (1993) Glutamate-dopamine interaction in the basalganglia: relationship to Parkinson's disease. J Neural Transm [GenSect] 91: 255–269
Imperato A, Honorè T, Jensen LH (1990) Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res 530: 223–228
Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 27: 490–497
Maura G, Giardi A, Raiteri M (1988) Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J Pharmacol Exp Ther 247: 680–684
Mercuri N, Bernardi G, Calabresi P, Cotugno A, Levi G, Stanzione P (1985) Dopamine decreases cell excitability in rat striatal neurons by pre- and postsynaptic mechanisms. Brain Res 358(1–2): 110–121
Mitchell PR, Doggett NS (1980) Modulation of striatal [3H]glutamergic acid release by dopaminergic drugs. Life Sci 26: 2073–2081
Mundinger F, Milios E (1985) Erfahrungen mit Memantine bei der Behandlung schwerer spastischer und extrapyramidaler Bewegungsstörungen in Kombination mit der stereotaktischen Operation. Nervenarzt 56: 106–109
O'Brien MW, Oltmans GA, Lorden JF (1990) Decreased quisqualate-sensitive glutamate binding in the cerebellar cortex of dystonic rat. Soc Neurosci Abstr 16: 1191
Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles, Brain Information Service/Brain Research Institute, UCLA
Robertson HA (1986) Cerebral decortication reverses the effect of amphetamine on D2 dopamine binding site density. Neurosci Lett 72: 325–329
Staedt J, Windt H, Hajak G, Stoppe G, Rudolph G, Ensink FBM, Hildebrandt J, Rüther E (1993) Cluster arousal analysis in chronic pain disturbed sleep. J Sleep Res 2: 134–137
Staedt J, Stoppe G, Kögler A, Munz DL, Hajak G, Staedt U, Riemann H, Rüther E (1994) Nächtliches Myoklonie-Syndrom (NMS) und Restless-Legs-Syndrom (RLS)-Ubersicht und Fallbeschreibung. Fortschr Neurol Psychiat 62: 88–93
Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E (1995a) Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2 receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 8–10
Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E (1995b) Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm [GenSect] 99: 187–193
Trendelenburg U (1966) Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol Rev 18: 629–640
Zipp F, Baas H, Fischer P-A (1993) Lamotrigine — antiparkinsonian activity by blockade of glutamate release? J Neural Transm [P-D Sect] 5: 67–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Staedt, J., Stoppe, G., Riemann, H. et al. Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports. J. Neural Transmission 103, 355–361 (1996). https://doi.org/10.1007/BF01271247
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01271247